Merck has decided to exercise its option to develop and commercialize the personalized cancer vaccine (PCV) mRNA-4157/V940 with Moderna.
Aptar Pharma has added another element to its suite of digital support tools for patients as they make their journey through the healthcare system.
Montreal, Canada-based Theratechnologies has received FDA’s approval for Trogarzo (ibalizumab-uiyk) for administration by intravenous (IV) push.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.